226 related articles for article (PubMed ID: 22519910)
1. The advent of AAV9 expands applications for brain and spinal cord gene delivery.
Dayton RD; Wang DB; Klein RL
Expert Opin Biol Ther; 2012 Jun; 12(6):757-66. PubMed ID: 22519910
[TBL] [Abstract][Full Text] [Related]
2. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.
Foust KD; Nurre E; Montgomery CL; Hernandez A; Chan CM; Kaspar BK
Nat Biotechnol; 2009 Jan; 27(1):59-65. PubMed ID: 19098898
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of AAV9 Mediated Trastuzumab Expression in Rat Brain Following Systemic and Local Administration.
Chowdhury EA; Ahuja M; Wu S; Liu S; Huang HW; Kumar M; Sunkara KS; Ghobrial A; Chandran J; Jamier T; Perkinton M; Meno-Tetang G; Shah DK
J Pharm Sci; 2024 Jan; 113(1):131-140. PubMed ID: 37659717
[TBL] [Abstract][Full Text] [Related]
4. Physical positioning markedly enhances brain transduction after intrathecal AAV9 infusion.
Castle MJ; Cheng Y; Asokan A; Tuszynski MH
Sci Adv; 2018 Nov; 4(11):eaau9859. PubMed ID: 30443600
[TBL] [Abstract][Full Text] [Related]
5. A single direct injection into the left ventricular wall of an adeno-associated virus 9 (AAV9) vector expressing extracellular superoxide dismutase from the cardiac troponin-T promoter protects mice against myocardial infarction.
Prasad KM; Smith RS; Xu Y; French BA
J Gene Med; 2011 Jun; 13(6):333-41. PubMed ID: 21674736
[TBL] [Abstract][Full Text] [Related]
6. Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9.
ElMallah MK; Falk DJ; Lane MA; Conlon TJ; Lee KZ; Shafi NI; Reier PJ; Byrne BJ; Fuller DD
Hum Gene Ther Methods; 2012 Apr; 23(2):148-56. PubMed ID: 22693957
[TBL] [Abstract][Full Text] [Related]
7. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates.
Gray SJ; Matagne V; Bachaboina L; Yadav S; Ojeda SR; Samulski RJ
Mol Ther; 2011 Jun; 19(6):1058-69. PubMed ID: 21487395
[TBL] [Abstract][Full Text] [Related]
8. An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery.
Huang Q; Chan KY; Wu J; Botticello-Romero NR; Zheng Q; Lou S; Keyes C; Svanbergsson A; Johnston J; Mills A; Lin CY; Brauer PP; Clouse G; Pacouret S; Harvey JW; Beddow T; Hurley JK; Tobey IG; Powell M; Chen AT; Barry AJ; Eid FE; Chan YA; Deverman BE
Science; 2024 Jun; 384(6701):1220-1227. PubMed ID: 38753766
[TBL] [Abstract][Full Text] [Related]
9. Efficient Gene Transfer to the Central Nervous System by Single-Stranded Anc80L65.
Hudry E; Andres-Mateos E; Lerner EP; Volak A; Cohen O; Hyman BT; Maguire CA; Vandenberghe LH
Mol Ther Methods Clin Dev; 2018 Sep; 10():197-209. PubMed ID: 30109242
[TBL] [Abstract][Full Text] [Related]
10. In vivo selection in non-human primates identifies AAV capsids for on-target CSF delivery to spinal cord.
Hanlon KS; Cheng M; Ferrer RM; Ryu JR; Lee B; De La Cruz D; Patel N; Espinoza P; Santoscoy MC; Gong Y; Ng C; Nguyen DM; Nammour J; Clark SW; Heine VM; Sun W; Kozarsky K; Maguire CA
Mol Ther; 2024 Jun; ():. PubMed ID: 38845196
[TBL] [Abstract][Full Text] [Related]
11. Intraspinal injection of adeno-associated viruses into the adult mouse spinal cord.
Chaterji S; Barik A; Sathyamurthy A
STAR Protoc; 2021 Sep; 2(3):100786. PubMed ID: 34505088
[TBL] [Abstract][Full Text] [Related]
12. Prenatal AAV9-GFP administration in fetal lambs results in transduction of female germ cells and maternal exposure to virus.
Borges B; Varthaliti A; Schwab M; Clarke MT; Pivetti C; Gupta N; Cadwell CR; Guibinga G; Phillips S; Del Rio T; Ozsolak F; Imai-Leonard D; Kong L; Laird DJ; Herzeg A; Sumner CJ; MacKenzie TC
Mol Ther Methods Clin Dev; 2024 Jun; 32(2):101263. PubMed ID: 38827250
[TBL] [Abstract][Full Text] [Related]
13. New AAV9 engineered variants with enhanced neurotropism and reduced liver off-targeting in mice and marmosets.
Giannelli SG; Luoni M; Iannielli A; Middeldorp J; Philippens I; Bido S; Körbelin J; Broccoli V
iScience; 2024 May; 27(5):109777. PubMed ID: 38711458
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9.
Saraiva J; Nobre RJ; Pereira de Almeida L
J Control Release; 2016 Nov; 241():94-109. PubMed ID: 27637390
[TBL] [Abstract][Full Text] [Related]
15. Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection.
McLean JR; Smith GA; Rocha EM; Hayes MA; Beagan JA; Hallett PJ; Isacson O
Neurosci Lett; 2014 Jul; 576():73-8. PubMed ID: 24882721
[TBL] [Abstract][Full Text] [Related]
16. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates.
Gray SJ; Nagabhushan Kalburgi S; McCown TJ; Jude Samulski R
Gene Ther; 2013 Apr; 20(4):450-9. PubMed ID: 23303281
[TBL] [Abstract][Full Text] [Related]
17. Biology of adeno-associated viral vectors in the central nervous system.
Murlidharan G; Samulski RJ; Asokan A
Front Mol Neurosci; 2014; 7():76. PubMed ID: 25285067
[TBL] [Abstract][Full Text] [Related]
18. Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain.
Aschauer DF; Kreuz S; Rumpel S
PLoS One; 2013; 8(9):e76310. PubMed ID: 24086725
[TBL] [Abstract][Full Text] [Related]
19. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates.
Meyer K; Ferraiuolo L; Schmelzer L; Braun L; McGovern V; Likhite S; Michels O; Govoni A; Fitzgerald J; Morales P; Foust KD; Mendell JR; Burghes AH; Kaspar BK
Mol Ther; 2015 Mar; 23(3):477-87. PubMed ID: 25358252
[TBL] [Abstract][Full Text] [Related]
20. Adeno-associated virus vectors and neurological gene therapy.
Ojala DS; Amara DP; Schaffer DV
Neuroscientist; 2015 Feb; 21(1):84-98. PubMed ID: 24557878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
